中国医院用药评价与分析Issue(10)：887-889,3.DOI:10.14009/j.issn.1672-2124.2014.10.010
钠-葡萄糖共转运蛋白-2抑制剂的药理学与临床评价
Pharmacology of and Clinical Evaluation on Sodium Glucose Co Transporter 2 Inhibitors
摘要
Abstract
OBJECTIVE:To explore the pharmacology of and clinical evaluation about sodium glucose co transporter 2 (SGLT-2) Inhibitors. METHODS:By reviewing pertinent literature both at home and abroad about the related articles of sodium-glucose cotransporter-2 to evaluate the pharmacology of and clinical evaluation. RESULTS & CONCLUSIONS:Sodium-glucose cotransporter-2 inhibitor is completely different form oral hypoglycemic agent in the mechanism of action in that its action doesn’t rely on the promotion of pancreaticβ-cell to secrete insulin nor dependent on insulin, however, it can delay the progression of diabetes and lower the risk of hypoglycaemia, which thus has a good application prospect,but it’s safety,economy and the clinical benefit need more long-term clinical studies to prove.关键词
坎格列净/2型糖尿病/钠-葡萄糖共转运蛋白-2抑制剂/临床评价Key words
Canagliflozin/Type 2 diabetes/Sodium glucose cotransporter-2 inhibitor/Clinical evaluation分类
医药卫生引用本文复制引用
王建民,付燕霞..钠-葡萄糖共转运蛋白-2抑制剂的药理学与临床评价[J].中国医院用药评价与分析,2014,(10):887-889,3.
